Prolonged-release pirfenidone prevents myocardial fibrosis in a mouse nonalcoholic steatohepatitis model

Prolonged-release pirfenidone prevents myocardial fibrosis in a mouse nonalcoholic steatohepatitis model

Bibliographic Details
Main Authors:	J. Gutiérrez-Cuevas, A. Sandoval-Rodríguez, C. Monroy-Ramírez, A. Santos-García, J. Armendáriz-Borunda
Format:	Article
Language:	English
Published:	Elsevier 2020-09-01
Series:	Annals of Hepatology
Online Access:	http://www.sciencedirect.com/science/article/pii/S1665268120301022

Similar Items

Prolonged-release pirfenidone decreases hepatic miRNAs expression in a NAFLD/NASH experimental model
by: R. Escutia-Gutiérrez, et al.
Published: (2020-09-01)

Cellular and molecular characterization of the pirfenidone effects on an hepatocarcinogésis experimental model
by: J.A. Silva-Gómez, et al.
Published: (2020-09-01)

Nonalcoholic steatohepatitis (NASH) with diabetes: predictors of liver fibrosis
by: D.N. Amarapurkar, et al.
Published: (2006-01-01)

Pirfenidone induces epigenetic changes modulating the activity of the ppargamma-SIRT1-DNMT1 axis in hepatic stellate cells
by: H.C. Monroy-Ramírez, et al.
Published: (2020-09-01)

Advances and challenges in the management of advanced fibrosis in nonalcoholic steatohepatitis
by: Mehmet Sayiner, et al.
Published: (2018-11-01)

A simple method for inducing nonalcoholic steatohepatitis with fibrosis
by: Leyla Yahaghi, et al.
Published: (2019-12-01)

Analysis of the molecular interaction of pirfenidone with PPAR-gamma and effects on the beta-catenine pathway in HEPG2 line
by: H.C. Monroy-Ramírez, et al.
Published: (2020-09-01)

Transaminases and gamma glutamyl transpeptidase for detecting nonalcoholic steatohepatitis and fibrosis in nonalcoholic fatty liver disease
by: Shahinul Alam, et al.
Published: (2016-07-01)

Effect of Prolonged-Release Pirfenidone on Renal Function in Septic Acute Kidney Injury Patients: A Double-Blind Placebo-Controlled Clinical Trial
by: Jonathan S. Chávez-Iñiguez, et al.
Published: (2021-01-01)

Plasma eicosanoids as noninvasive biomarkers of liver fibrosis in patients with nonalcoholic steatohepatitis
by: Cyrielle Caussy, et al.
Published: (2020-05-01)

Necroptosis in Nonalcoholic Steatohepatitis
by: Jérémie Gautheron, PhD, et al.
Published: (2015-05-01)

S-nitroso-N-acetylcysteine attenuates liver fibrosis in experimental nonalcoholic steatohepatitis
by: Mazo DF, et al.
Published: (2013-06-01)

Recent Insight into the Role of Fibrosis in Nonalcoholic Steatohepatitis-Related Hepatocellular Carcinoma
by: Antonio Sircana, et al.
Published: (2019-04-01)

Nonalcoholic Steatohepatitis: An Evolving Diagnosis
by: Brent A Neuschwander-Tetri
Published: (2000-01-01)

Psoralea corylifolia L. Attenuates Nonalcoholic Steatohepatitis in Juvenile Mouse
by: Lishan Zhou, et al.
Published: (2017-11-01)

The metabolic basis of nonalcoholic steatohepatitis
by: Manu V. Chakravarthy, et al.
Published: (2020-10-01)

Health Care Use and Costs Among Patients With Nonalcoholic Steatohepatitis With Advanced Fibrosis Using the Fibrosis‐4 Score
by: Stuart C. Gordon, et al.
Published: (2020-07-01)

Pirfenidone treatment of idiopathic pulmonary fibrosis
by: Arata Azuma
Published: (2012-04-01)

Application of Pirfenidone anti-fibrosis in ophthalmology
by: Xiao Yang, et al.
Published: (2013-08-01)

Is pirfenidone effective for idiopathic pulmonary fibrosis?
by: Alejandro Jeldres, et al.
Published: (2017-03-01)

Role of pirfenidone in the management of pulmonary fibrosis
by: Meyer KC, et al.
Published: (2017-04-01)

Pirfenidone treatment of idiopathic pulmonary fibrosis
by: Ye Gan, et al.
Published: (2011-02-01)

Establishment and Comparison of Juvenile Female Mouse Models of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis
by: Lishan Zhou, et al.
Published: (2018-01-01)

Pirfenidone modifies hepatic miRNAs expression in a model of MAFLD/NASH
by: Rebeca Escutia-Gutiérrez, et al.
Published: (2021-06-01)

Elevated oxysterol levels in human and mouse livers reflect nonalcoholic steatohepatitis[S]
by: Tina Raselli, et al.
Published: (2019-07-01)

Increasing metabolic co-morbidities are associated with higher risk of advanced fibrosis in nonalcoholic steatohepatitis.
by: Robert J Wong, et al.
Published: (2019-01-01)

Efficacy and safety of pirfenidone for idiopathic pulmonary fibrosis
by: Takeda Y, et al.
Published: (2014-03-01)

Steatohepatitis Is Not Associated with an Increased Risk for Fibrosis Progression in Nonalcoholic Fatty Liver Disease
by: Hannes Hagström, et al.
Published: (2018-01-01)

S-nitroso-N-acetylcysteine attenuates liver fibrosis in experimental nonalcoholic steatohepatitis [Corrigendum]
by: Mazo DF, et al.
Published: (2013-09-01)

New Aspects of Lipotoxicity in Nonalcoholic Steatohepatitis
by: Nahum Mendez-Sanchez, et al.
Published: (2018-07-01)

Pathogenesis of Nonalcoholic Steatohepatitis: An Overview
by: Gopanandan Parthasarathy, et al.
Published: (2020-04-01)

Liver Fibrogenesis in Nonalcoholic Steatohepatitis
by: Xiong eMa
Published: (2012-07-01)

Recent update: Nonalcoholic steatohepatitis
by: Vivek Hande, et al.
Published: (2018-01-01)

HISTOPATOLOGICAL ASPECTS IN NONALCOHOLIC STEATOHEPATITIS
by: Anca-Mirela Pasparan, et al.
Published: (2008-02-01)

IMAGING DIAGNOSIS OF NONALCOHOLIC STEATOHEPATITIS
by: Anca Smaranda Farmazon, et al.
Published: (2018-09-01)

Familial Hypobetalipoproteinemia-Induced Nonalcoholic Steatohepatitis
by: Mindy C.W. Lam, et al.
Published: (2012-07-01)

Lipoprotein subclass metabolism in nonalcoholic steatohepatitis[S]
by: Ville T. Männistö, et al.
Published: (2014-12-01)

Collagen Characterization in a Model of Nonalcoholic Steatohepatitis with Fibrosis; A Call for Development of Targeted Therapeutics
by: Anthony J. Pellicano, et al.
Published: (2021-06-01)

Pirfenidone in idiopathic pulmonary fibrosis: Is there a role?
by: I. Galal
Published: (2014-10-01)

Nonalcoholic Steatohepatitis and HCC in a Hyperphagic Mouse Accelerated by Western DietSummary
by: Souradipta Ganguly, et al.
Published: (2021-01-01)